Other generics companies, such as Cipla and Mylan Inc.
WSJ: Researchers Manipulate HIV Drug's Chemistry to Lower Cost
Pending confirmatory studies, suspend approvals of the other generics.
FORBES: A Drug Recall That Should Frighten Us All About The FDA
Competition among other generics will drive down consumer prices, creating a 30% drop when the first rivals step in and an 80% discount once 20 or more competitors pile on, according to researchers at Duke University.
To encourage generics makers to challenge patents on drugs, and introduce cheaper copies, an American law passed in 1984 says that the first one to do so will get a 180-day exclusivity period, in which no other generics maker can sell versions of the drug in question, as Ranbaxy supposedly won with Lipitor.
Many companies now have special drug benefit plans in which employees have no deductible and pay sliding fees per prescription designed to steer them to generics and other cheaper drugs.
Generics from other manufacturers have not been recalled.
FORBES: Generic Lipitor Recalled - Another Sign The FDA Needs Help?
But should this narrowly differentiated improvement demand a big premium over other ADHD alternatives, especially generics?
Where intellectual property rights are making commodities unaffordable for the poorest countries, Save the Children also wants industry and other stakeholders to facilitate the development of generics.
In North America, health technology, a sector which includes major pharmaceutical companies and other drug-makers like companies which make generics, eeked out a 0.43% gain over the past two weeks, according to FactSet Research Systems.
Such machinations may suit brand-owners and generics makers whose old enmity is fading in other ways too (see article).
They prefer proteins, cell therapies, and other newer types of medicines that will continue to generate revenue even if patents expire and generics emerge.
In an interview, Jennifer Cohn, medical coordinator for MSF's access campaign, said the ruling reinforces the idea that India won't patent drugs that are "not significantly innovative, " leaving generics companies free to produce many products for domestic use or for export to other countries where the drugs aren't protected by patent.
The losers, then, might be the other side of that see-saw, the companies that have invested most heavily in the generics: Novartis, Teva Pharmaceutical Industries, and Ranbaxy Laboratories.
FORBES: Supreme Court Helps Big Pharma Stay Fat And Happy In Sorrell Ruling
On the other hand, Roche, a Swiss rival to Novartis, has said that it sees no future in entering the generics market.
This means the biotech does not need to split the revenue with other drug makers and analysts at GlobalData note this is a significant advantage as Gilead eventually faces a growing threat from generics.
应用推荐